Canada · Delayed Price · Currency is CAD KP Tissue Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw strong revenue and margin growth, with Adjusted EBITDA up 26% year-over-year and net income turning positive. Market share gains, operational improvements, and strategic investments position the business for continued growth in 2026.
-
Q3 2025 saw robust revenue and EBITDA growth, driven by strong consumer and away-from-home performance, premium product expansion, and operational improvements. The balance sheet was further deleveraged, and a new U.S. tissue plant was announced to support future growth.
-
Adjusted EBITDA rose 11% year-over-year to $72.5 million on 5% revenue growth, with strong consumer segment gains and U.S. expansion offsetting softer away-from-home sales. Q3 2025 EBITDA is guided to $75–$80 million, supported by efficiency investments and margin management.
-
The AGM highlighted record revenue and EBITDA growth in 2024, strong Q1 2025 results, and successful expansion of the Sherbrooke plant. Directors and auditors were re-elected with overwhelming support, and strategic focus remains on sustainability, brand growth, and managing tariff risks.
-
Q1 2025 saw double-digit revenue and EBITDA growth, driven by strong sales in both Canada and the U.S., improved pricing, and operational efficiencies. The Sherbrooke expansion is on track to boost margins, while contingency plans address trade and supply risks.
Fiscal Year 2024
-
Record 2024 revenue and adjusted EBITDA were achieved, with Q4 revenue up 11.9% year-over-year. About one-third of revenue faces U.S. tariff risk, but mitigation plans and strong liquidity support ongoing growth. Net loss in Q4 was driven by FX losses and higher expenses.
-
Double-digit revenue growth in Q3 2024 was driven by higher sales and favorable pricing, but adjusted EBITDA declined due to increased input costs. The Sherbrooke plant expansion was completed, boosting capacity, and market share gains were achieved in key categories.
-
Q2 2024 saw 9.3% revenue growth and 18.6% higher Adjusted EBITDA, with strong performance in both consumer and away-from-home segments. Price increases are set for September to offset record pulp costs, and the Sherbrooke expansion remains on track for Q4.
-
The meeting featured strong 2023 financial results, with record revenue and EBITDA, and outlined strategic growth initiatives including major manufacturing expansions. Key votes passed with large majorities, and management addressed challenges such as rising pulp prices and market competition.